C4 Therapeutics, Inc.
CCCCNASDAQHealthcare● Active
$3.59
$-0.26(-6.75%)
Market Cap$297349605
P/E Ratio—
52W High$4.598
52W Low$1.36
C4 Therapeutics, Inc. (CCCC) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CCCC · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $35.95M | $35.58M | $20.76M | $31.10M | $45.78M |
| Cost of Revenue | $7.97M | $0.00M | $7.74M | $0.00M | $0.00M |
| Gross Profit | $27.97M | $35.58M | $13.02M | $31.10M | $45.78M |
| Gross Margin %(computed) | 77.81% | 100.00% | 62.72% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $104.24M | $110.64M | $117.71M | $117.84M | $94.67M |
| G&A Expenses | $36.20M | $42.12M | $42.08M | $42.79M | $33.25M |
| Total Operating Expenses | $132.46M | $155.20M | $152.05M | $160.63M | $127.92M |
| Operating Income | ($104.49M) | ($119.61M) | ($139.03M) | ($129.53M) | ($82.13M) |
| Operating Margin %(computed) | -290.68% | -336.15% | -669.84% | -416.56% | -179.39% |
| Interest Income | $0.00M | $14.43M | $9.81M | $3.58M | $0.39M |
| Interest Expense | $0.00M | $0.00M | $1.37M | $2.22M | $2.15M |
| Income Before Tax | ($104.87M) | ($105.19M) | ($131.21M) | ($128.18M) | ($83.89M) |
| Income Tax Expense | $0.12M | $0.13M | $1.28M | $0.00M | $0.00M |
| Net Income | ($104.99M) | ($105.32M) | ($132.49M) | ($128.18M) | ($83.89M) |
| Net Margin %(computed) | -292.08% | -295.96% | -638.34% | -412.19% | -183.23% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.27 | $-1.52 | $-2.67 | $-2.62 | $-1.82 |
| Wtd Avg Shares | 82.89M | 69.37M | 49.64M | 48.86M | 46.04M |
| EBITDA | ($102.91M) | ($103.37M) | ($122.10M) | ($124.28M) | ($80.25M) |
| EBITDA Margin %(computed) | -286.29% | -290.49% | -588.28% | -399.68% | -175.29% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more C4 Therapeutics, Inc. data
About C4 Therapeutics, Inc. (CCCC) Income Statement
C4 Therapeutics, Inc. (CCCC) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CCCC reported revenue of $0.04B, gross profit of $0.03B (gross margin 77.81%), and net income of ($0.10B) — a net profit margin of -292.08%.
Frequently asked questions
CCCC · 4 questionsC4 Therapeutics, Inc. (CCCC) reported revenue of $0.04B for 2025, up 1.0% year-over-year.
CCCC revenueCCCC salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08